List of Excipients in Branded Drug TACHOSIL

« Back to Dashboard

TachoSil Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 27, 2026

TachoSil is a fibrin sealant patch that combines human fibrinogen and human thrombin with an absorbable equine collagen sponge. Its commercial value comes from the integrated delivery system: the collagen matrix provides handling and tissue contact, while the protein coating forms a fibrin clot at the bleeding site. The strongest opportunities are product extensions for minimally invasive surgery, broader hospital procurement, animal-free materials, and manufacturing improvements that reduce cold-chain and plasma-derived raw-material exposure.

What is TachoSil and how does its formulation work?

TachoSil is an absorbable surgical patch containing human fibrinogen and human thrombin. The active coating is applied to an equine collagen sponge. When the yellow coating contacts fluid or bleeding tissue, thrombin converts fibrinogen into fibrin, creating a local clot and tissue-adherent seal [1].

Product attribute	TachoSil profile
Active substances	Human fibrinogen and human thrombin
Delivery system	Absorbable equine collagen sponge
Approximate loading	5.5 mg human fibrinogen and 2.0 IU human thrombin per cm²
Primary function	Adjunctive control of surgical bleeding
Administration	Topical application to bleeding tissue
Storage	Refrigerated storage is generally required
Dosage form	Sterile, single-use surgical patch
Major use areas	Hepatic, cardiovascular, vascular, thoracic and soft-tissue surgery, depending on jurisdiction
Product category	Fibrin sealant patch and combination surgical hemostat

TachoSil is not a conventional tablet or injectable drug. Its performance depends on the interaction among the protein coating, collagen substrate, moisture, compression, tissue adherence and resorption profile.

Which excipients are used in TachoSil?

The principal functional excipient is the equine collagen sponge. The protein formulation also contains stabilizing and buffering substances associated with fibrinogen and thrombin processing.

Public product information identifies the collagen carrier and lists formulation components such as human albumin, sodium chloride, sodium citrate, L-arginine hydrochloride, L-glutamic acid and water for injection, subject to the applicable market label [1].

Component	Functional role	Commercial importance
Equine collagen	Absorbable scaffold and tissue-contact matrix	Controls handling, adherence, wet strength and resorption
Human albumin	Protein stabilizer	Supports recovery and storage stability of plasma-derived proteins
Sodium chloride	Isotonicity control	Supports protein compatibility and formulation consistency
Sodium citrate	Buffering and anticoagulant-related control	Helps maintain protein stability during manufacturing
L-arginine hydrochloride	Protein solubility and aggregation control	Can improve recovery and reduce unwanted protein interactions
L-glutamic acid	Buffering and protein stabilization	Supports formulation pH and protein integrity
Water for injection	Solvent	Required for the aqueous protein-processing system

The collagen is not a passive filler. It is a core performance excipient with direct influence over product handling, hemostatic efficacy, tissue conformity, absorption and surgeon acceptance.

How does the TachoSil excipient strategy create product value?

TachoSil uses a matrix-based excipient strategy rather than a conventional liquid formulation. The collagen patch immobilizes fibrinogen and thrombin at the surgical site and gives surgeons a physical product that can be placed, cut and pressed onto irregular tissue.

Collagen as a functional delivery platform

The collagen matrix provides four commercial advantages:

1. It localizes the active proteins at the bleeding site.
2. It reduces the need for a separate applicator or spray device.
3. It permits use on broad, irregular or difficult-to-access surfaces.
4. It gives surgeons immediate visual identification through the coated patch.

The main development challenge is balancing porosity and absorbency against mechanical integrity. A highly porous sponge may absorb blood rapidly but lose strength when wet. A denser matrix may handle better but reduce fluid penetration and delay activation.

Protein stabilization

Fibrinogen and thrombin are sensitive to temperature, moisture, agitation and manufacturing stress. Albumin and amino-acid excipients can protect protein conformation and reduce aggregation. The commercial objective is not simply longer shelf life. It is consistent clot formation after storage, transport, package opening and application in a wet surgical field.

Animal-derived collagen

Equine collagen supports a mature and clinically familiar patch platform, but it creates commercial constraints:

• Animal-origin sourcing and traceability
• Species-specific supply risk
• Potential procurement restrictions
• Regulatory scrutiny of transmissible agents
• Perceived immunogenicity concerns
• Limits on use in certain markets or hospitals

An animal-free matrix would not be a routine reformulation. It would require evidence that the substitute maintains mechanical strength, tissue adherence, absorption, sterility and hemostatic performance.

What formulations and excipient extensions could compete with TachoSil?

The most credible formulation opportunities are platform extensions rather than simple ingredient substitutions.

Synthetic or recombinant matrix systems

Potential alternatives include synthetic absorbable polymers, recombinant collagen, gelatin-free matrices and polysaccharide-based scaffolds. These systems could reduce animal-origin concerns, but they must match collagen's wet handling and tissue-contact behavior.

A substitute matrix has to satisfy several performance criteria:

Development criterion	Required commercial outcome
Wet tensile strength	Patch remains intact during placement and compression
Fluid uptake	Blood reaches the fibrinogen-thrombin coating
Adhesion	Product remains attached during the critical bleeding interval
Resorption	Matrix disappears without excessive inflammation or adhesions
Protein compatibility	Fibrinogen and thrombin retain activity
Sterilization tolerance	No loss of protein potency or matrix integrity
Packaging stability	Product survives refrigerated distribution and operating-room handling

Higher-loading patches

Higher protein loading could target severe bleeding or larger surgical surfaces. The limitation is that increased loading may raise cost, alter drying behavior, increase protein instability and create regulatory questions about systemic exposure or thrombotic risk.

Thin, conformable patches

A thinner patch could improve use in minimally invasive and robotic procedures. The opportunity is strongest in thoracic, cardiac, urologic and gynecologic surgery, where access is limited and bulky products are difficult to position.

Pre-cut and anatomically shaped formats

Pre-cut shapes could reduce preparation time and product waste. Examples include strips for vascular anastomoses, circular patches for trocar access sites, and narrow formats for laparoscopic instruments.

Drug-device combinations

A future patch could incorporate an additional antimicrobial, anti-inflammatory or adhesion-reducing component. Such combinations would increase differentiation but would also create more complex compatibility, release, toxicology and regulatory requirements.

What is the FDA regulatory status of TachoSil?

TachoSil has been regulated in the United States as a surgical hemostatic product through the FDA medical-device pathway, while it is regulated as a medicinal product in the European Union [2,3].

The regulatory classification matters commercially:

• TachoSil is not treated like a standard small-molecule drug.
• The product does not rely on an ordinary ANDA generic pathway.
• A Paragraph IV challenge is not the principal U.S. entry mechanism.
• FDA clearance or approval for a competing patch would require product-specific evidence on safety, performance, manufacturing and sterility.
• A formulation change can trigger comparability, clinical or human-factors requirements depending on the change.

The U.S. regulatory record and the applicable product indication should be checked by market because surgical indications and labeling may differ across jurisdictions.

What is the Orange Book status of TachoSil?

TachoSil is not generally analyzed through the FDA Orange Book in the same way as an NDA-listed oral or injectable drug. Its primary U.S. regulatory framework is associated with a surgical hemostatic product rather than a conventional Orange Book drug listing.

As a result, commercial entry analysis should focus on:

• FDA device classification
• Premarket submissions
• Manufacturing controls
• Sterility and packaging validation
• Clinical or performance evidence
• Patent and trade-secret protection
• Hospital contracting and surgeon adoption

There is no standard Orange Book patent-certification framework equivalent to that used for an NDA-listed small molecule.

When does TachoSil lose exclusivity?

TachoSil does not have a single, publicly determinative exclusivity date comparable to the loss of five-year or three-year statutory exclusivity for a new chemical entity.

Its commercial protection is likely to derive from a combination of:

• Product and formulation patents
• Collagen-matrix manufacturing patents
• Protein-coating and drying processes
• Packaging and moisture-control technology
• Regulatory approval history
• Manufacturing know-how
• Surgeon familiarity and hospital contracts
• Plasma-derived raw-material controls

The practical entry date for a competing patch therefore depends less on one expiration date and more on whether a rival can demonstrate equivalent clinical performance and secure hospital adoption.

How strong is the TachoSil patent estate?

The strongest defensible protection is likely to be concentrated in process and product architecture rather than a broad composition-of-matter claim covering fibrinogen or thrombin.

Potential patent claim areas include:

Claim area	Potential strength
Fibrinogen-thrombin combination on a collagen carrier	Moderate, depending on claim scope and expiration
Specific collagen structure or treatment	Moderate to strong if narrowly engineered
Protein loading and distribution	Moderate
Drying or stabilization process	Strong where difficult to reproduce
Sterile packaging and moisture control	Moderate
Surgical use claims	Variable and jurisdiction-specific
Manufacturing know-how	Potentially strong if not publicly disclosed
Animal-free replacement matrix	Opportunity for new patent protection

The most valuable trade secrets may concern collagen processing, protein adsorption, drying parameters, potency control, release testing and packaging. A competitor may be able to design around a patent but still face substantial process-development costs.

No reliable current patent-expiration date should be assigned without a jurisdiction-specific patent-family search and legal-status review. The absence of a standard Orange Book listing makes that analysis more important, not less.

What generic entry risks exist for TachoSil?

The principal threat is not a conventional generic drug launch. It is substitution by another surgical hemostat.

Competitive categories

TachoSil competes with:

• Fibrin sealant liquids and sprays
• Oxidized regenerated cellulose products
• Gelatin sponges
• Thrombin-only matrices
• Gelatin-thrombin matrices
• Collagen hemostats
• Microporous polysaccharide spheres
• Synthetic sealants
• Flowable hemostatic agents
• Energy-based surgical devices

Competitors can enter by offering better storage, lower cost, faster application, broader indication coverage or improved compatibility with laparoscopic and robotic surgery.

Main substitution risks

Risk	Commercial effect
Lower-cost absorbable patch	Pressure on hospital price and formulary position
Room-temperature product	Reduces cold-chain and operating-room handling burden
Synthetic or recombinant matrix	Addresses animal-origin restrictions
Flowable hemostat	May perform better in irregular cavities
Smaller laparoscopic format	Improves procedural convenience
Stronger adhesion under anticoagulation	Supports cardiovascular and vascular adoption
Broader clinical evidence	Helps competitors win hospital protocols

Which companies challenge the TachoSil franchise?

The relevant competitive field includes manufacturers of fibrin sealants, collagen patches, thrombin matrices, gelatin products and synthetic surgical sealants. Major global participants have included Baxter, Ethicon, Pfizer, BD, Teleflex, Integra LifeSciences, B. Braun and other regional surgical-hemostasis suppliers.

The competitive comparison should be made at the procedure level rather than only by active ingredient. A surgeon selecting a hemostat typically evaluates application speed, visibility, adhesion, removal requirements, blood absorption, preparation steps and cost per controlled bleeding event.

What commercial opportunities exist for TachoSil excipient innovation?

1. Animal-free collagen replacement

An animal-free matrix could access hospitals with restrictions on equine-derived materials and could reduce supply-chain complexity. The opportunity is commercially meaningful only if the replacement maintains the handling characteristics surgeons associate with collagen patches.

2. Room-temperature stability

A formulation and packaging system that reduces refrigeration could lower distribution costs and simplify operating-room storage. This may require improved protein stabilization, moisture-barrier packaging or a redesigned dry-state matrix.

3. Robotic and laparoscopic formats

Narrow strips, foldable patches and instrument-compatible formats could improve adoption in minimally invasive procedures. The product would need controlled deployment without premature adhesion to the applicator or loss of coating.

4. Procedure-specific products

Procedure-specific SKUs could target liver resection, cardiac surgery, vascular anastomosis, lung surgery and urologic procedures. A focused clinical and economic dossier may support premium pricing over a general-purpose patch.

5. Lower-waste packaging

Small, sterile units and resealable outer packaging could reduce waste where only a small patch is required. This is important because unused surgical hemostat inventory is a direct cost to hospitals.

6. Combination with digital inventory systems

While not an excipient innovation, lot-level tracking and inventory management could improve plasma-derived product control, expiry management and hospital purchasing. This may support premium contracts with integrated delivery and supply services.

How does TachoSil compare with liquid fibrin sealants?

Attribute	TachoSil	Liquid fibrin sealant
Application	Direct patch placement	Spraying, dripping or dual-syringe application
Surface coverage	Strong for broad, accessible surfaces	Strong for irregular or deep surfaces
Handling	Preformed solid format	Requires preparation or applicator
Tissue contact	Matrix provides physical support	Depends on liquid distribution and clot formation
Excess removal	Patch may remain until absorbed	Usually no solid carrier
Minimally invasive use	Requires delivery-compatible format	Often adaptable through applicators
Key excipient issue	Matrix design and animal origin	Protein stability, viscosity and spray performance

TachoSil's advantage is controlled placement and physical reinforcement. Liquid products may be better for cavities, diffuse oozing or anatomically inaccessible sites.

What litigation and settlement issues affect TachoSil?

TachoSil's relevant legal risks are likely to involve patent validity, manufacturing processes, product liability, animal-derived materials, plasma sourcing and hospital contracting. Because the product is not principally an Orange Book small-molecule product, Paragraph IV litigation is not the central risk model.

Potential dispute areas include:

• Collagen-matrix composition
• Protein-coating processes
• Patch drying and stabilization
• Surgical-use claims
• Sterility and packaging methods
• Plasma-derived ingredient sourcing
• Product performance and failure-to-hemostat allegations
• Contracting or distribution rights

A current litigation conclusion requires a jurisdiction-specific docket and patent-family review. Product labels and regulatory records alone do not establish whether a patent dispute or settlement remains active.

What revenue exposure does TachoSil create?

TachoSil generates value through high unit economics in specialist procedures rather than broad outpatient volume. Revenue is exposed to:

• Elective surgery volumes
• Cardiovascular and hepatic procedure trends
• Hospital budget pressure
• Competition from lower-cost hemostats
• Operating-room preference
• Reimbursement treatment of surgical supplies
• Product availability and cold-chain reliability
• Clinical evidence supporting reduced transfusion, operating time or reoperation

The strongest commercial defense is procedure-specific health-economic evidence. A patch that costs more per unit can retain share if it reduces blood loss, shortens procedure time or avoids conversion to another hemostatic method.

Key Takeaways

• TachoSil's core excipient is its equine collagen matrix, which is also its principal differentiation and supply-chain vulnerability.
• Human fibrinogen and thrombin provide the hemostatic activity; albumin, salts and amino acids support protein formulation stability.
• The product is better analyzed as an integrated surgical hemostat than as a conventional drug.
• Orange Book and Paragraph IV frameworks are not the primary U.S. entry tools.
• The most attractive innovation areas are animal-free matrices, room-temperature stability, minimally invasive formats and procedure-specific patches.
• Competitive threats come from alternative surgical hemostats, not only from direct patch replicas.
• Manufacturing know-how may be as important as patent protection in collagen processing, protein coating, drying and packaging.
• Hospital adoption depends on handling, clinical evidence, price per controlled bleeding event and supply reliability.

FAQs

Is TachoSil a drug or a medical device?

TachoSil is a combination surgical hemostat. Its regulatory classification differs by jurisdiction. It is treated as a medicinal product in the European Union and under a medical-device-related pathway in the United States.

Is equine collagen an active ingredient in TachoSil?

No. Equine collagen is the absorbable carrier matrix. Human fibrinogen and human thrombin are the hemostatic active substances.

Can TachoSil be reformulated with bovine or recombinant collagen?

Potentially, but the change would require evidence on tissue adherence, mechanical strength, absorption, protein activity, sterility, immunogenicity and manufacturing comparability. A new matrix could also require a new regulatory strategy.

Does TachoSil have a generic equivalent?

A conventional pharmaceutical generic is not the expected entry model. Competition would more likely arise from another approved surgical hemostat, collagen patch, fibrin sealant or synthetic matrix.

What is the largest commercial weakness of TachoSil?

The main weaknesses are dependence on plasma-derived proteins, animal-derived collagen, refrigerated distribution and premium pricing relative to lower-cost hemostatic materials.

References

1. European Medicines Agency. (n.d.). TachoSil: EPAR product information. European Union.
2. U.S. Food and Drug Administration. (n.d.). TachoSil surgical hemostatic product: Premarket approval and device information.
3. U.S. Food and Drug Administration. (2023). Guidance for industry and FDA staff: Surgical hemostatic devices.
4. European Medicines Agency. (2019). Guideline on the quality, non-clinical and clinical aspects of medicinal products containing recombinant or human plasma-derived fibrin sealants.
5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: Sterility, biological reactivity and pharmaceutical packaging standards.